Go to Content Go to Navigation Go to Navigation Go to Site Search Homepage

Welcome to “The Quickie”

Welcome to “The Quickie” — Planned Parenthood Action Fund’s daily tipsheet on the top health care & reproductive rights stories of the day. You can read “The Quickie'' online here.

In today’s Quickie: Elected officials and organizations file amicus briefs in support of protecting medication abortion, and PPMT director Dr. Dickman highlights research on the impact of abortion bans on rape-related pregnancies.

DOZENS OF NEW AMICUS BRIEFS SOUND THE ALARM ON PROTECTING MEDICATION ABORTION: Underscoring the unprecedented nature of a lawsuit that could wreak havoc on abortion access nationwide, scores of elected officials and organizations filed new amicus briefs in advance of the Supreme Court oral arguments in Alliance for Hippocratic Medicine et al v. U.S. Food and Drug Administration. The case challenges evidence-based actions by the FDA that expanded access to mifepristone and will determine the conditions under which the medicine, which is commonly used for medication abortion, can remain on the market. Nearly three dozen briefs submitted point to the outrage over a politically charged maneuver to rob people of the right to control their own bodies. Oral arguments will be held on March 26. 

From the brief submitted by 237 reproductive health, rights, and justice organizations —  including Planned Parenthood Federation of America:

“Restrictions on mifepristone would have widespread detrimental consequences. The Fifth Circuit’s decision reimposes a burdensome in-person dispensing requirement and narrows the types of medical professionals who can become certified prescribers. As a  result of these restrictions, even people in states where abortion remains legal and protected could find themselves unable to timely access mifepristone, imperiling access to abortion and jeopardizing the health and autonomy of those denied care. Clinics and providers—including several amici—could find themselves unable to effectively provide competent and much-needed medical care.

“Far from protecting patient health, the Fifth Circuit’s decision will have severe and damaging consequences unsupported by law or science. The decision should be reversed.”

From the largest sexual and reproductive health brief in Congressional history, filed by 263 members of Congress:

“...this Court’s reversal of the Fifth Circuit’s order with respect to FDA’s 2016 and 2021 actions is necessary to mitigate the imminent harm facing members of the public, many of whom rely on the availability of mifepristone for reproductive care—and many more of whom rely on the integrity of FDA’s drug approval process for continued access to life-improving and lifesaving drugs. Congress intended to—and did—vest authority in FDA to evaluate and ensure the safety and efficacy of drugs in the United States…”

Read more here.

 

THE NEW ABNORMAL: SHOCKING POST-ROE RAPE STUDY — Dr. Samuel Dickman, medical director at Planned Parenthood of Montana, joined The New Abnormal podcast to discuss new research that estimated 65 thousand rape-related pregnancies since the overturning of Roe last year. Dr. Dickman, an abortion doctor in Texas before moving to Montana to continue providing care, shares his experiences working with patients seeking abortion access who are assault survivors. 

“I think the more we can acknowledge that it's a critically important service that so many people have benefited from and hopefully will continue to benefit from, the better. Part of destigmatizing abortion is just being able to talk about it in all its forms, whether that's for someone who has a major complication during pregnancy and needs an abortion to save her life, whether it's for a survivor of rape who, if forced to continue that pregnancy, would also be forced to remain in a relationship with their abuser, or whether it's for the mother of three who can't afford and doesn't want to have another child. You know, all of those patients deserve to be able to access medical care, and all of them are important to talk about.”

Listen to the full episode here.

Planned Parenthood cares about your data privacy. We and our third-party vendors use cookies and other tools to collect, store, monitor, and analyze information about your interaction with our site to improve performance, analyze your use of our sites and assist in our marketing efforts. You may opt out of the use of these cookies and other tools at any time by visiting Cookie Settings. By clicking “Allow All Cookies” you consent to our collection and use of such data, and our Terms of Use. For more information, see our Privacy Notice.

Cookie Settings

Planned Parenthood cares about your data privacy. We and our third-party vendors, use cookies, pixels, and other tracking technologies to collect, store, monitor, and process certain information about you when you access and use our services, read our emails, or otherwise engage with us. The information collected might relate to you, your preferences, or your device. We use that information to make the site work, analyze performance and traffic on our website, to provide a more personalized web experience, and assist in our marketing efforts. We also share information with our social media, advertising, and analytics partners. You can change your default settings according to your preference. You cannot opt-out of our Necessary Cookies as they are deployed to ensure the proper functioning of our website (such as prompting the cookie banner and remembering your settings, to log into your account, to redirect you when you log out, etc.). For more information, please see our Privacy Notice.

Marketing

On

We use online advertising to promote our mission and help constituents find our services. Marketing pixels help us measure the success of our campaigns.

Performance

On

We use qualitative data, including session replay, to learn about your user experience and improve our products and services.

Analytics

On

We use web analytics to help us understand user engagement with our website, trends, and overall reach of our products.